(S)-Mephenytoin
(Synonyms: 甲秦皮素,(S)-5-Ethyl-3-methyl-5-phenylhydantoin) 目录号 : GC14486
S-Mephenytoin (5-phenyl-5-ethyl-N-methylhydantoin) 是一种抗惊厥药，通过 N-去甲基化和 4-羟基化（芳环）代谢。
Cas No.:70989-04-7
Sample solution is provided at 25 µL, 10mM.
S-Mephenytoin (5-phenyl-5-ethyl-N-methylhydantoin) is an anticonvulsive drug which is metabolized by N-demethylation and 4-hydroxylation (of the aromatic ring). CYP2C19 genotype is a major determined factor for metabolisms of S-Mephenytoin. The formations of 4X-hydroxymephenytoin, S-Mephenytoin’s metabolite is CYP2C19 genotype dependent.[1][2]
The genetic polymorphism of CYP2C19 was revealed by the discovery of deficient 4’-hydroxylation of mephenytoin (3-methyl-5-phenyl-5 ethylhydantoin; Mesantoin). Human can be characterized as poor (PM) or extensive metabolizers (EM) with use of racemic mephenytoin as a phenotyping drug, and CYP2C19 has been identified as the major S-Mephenytoin (S-MP) hydroxylase in human. This polymorphism affects the metabolism of many other clinically important drugs such as diazepam, omeprazole (OP), imipramine, propranolol, and chloroguanide.[1]
Rabbit anti-human cytochrome b5 inhibited NADH-cytochrome-c reductase and S-Mephenytoin 4-hydroxylase activities in human liver microsomes. In the presence of cytochrome b5, the Km value for S-Mephenytoin was 1.25 mM with all five purified cytochrome P-450s preparations, and Vmax values were 0.8-1.25 nmol of 4-hydroxy product formed per min/nmol of P-450. P-45OMP is a relatively selective P-450 form that metabolizes substituted hydantoins well.[2]
References:
[1]. Zhou HH. CYP2C19 genotype determines enzyme activity and inducibility of S-Mephenytoin hydroxylase. Clin Chim Acta. 2001 Nov;313(1-2):203-8.
[2]. Shimada T, et al. Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction. J Biol Chem. 1986 Jan 15;261(2):909-21.
S-Mephenytoin (5-phenyl-5-ethyl-N-methylhydantoin) 是一种抗惊厥药，通过 N-去甲基化和 4-羟基化（芳环）代谢。 CYP2C19 基因型是 S-美芬妥英代谢的主要决定因素。 S-Mephenytoin 的代谢物 4X-hydroxymephenytoin 的形成依赖于 CYP2C19 基因型。[1][2]
美苯妥英（3-甲基-5-苯基-5 乙基乙内酰脲；美山妥英）的 4'-羟基化缺陷的发现揭示了 CYP2C19 的遗传多态性。使用外消旋美苯妥英作为表型药物，人类可被表征为弱代谢者 (PM) 或强代谢者 (EM)，并且 CYP2C19 已被确定为人类中主要的 S-美芬妥英 (S-MP) 羟化酶。这种多态性影响许多其他临床重要药物的代谢，例如地西泮、奥美拉唑 (OP)、丙咪嗪、普萘洛尔和氯胍。[1]
兔抗人细胞色素 b5 抑制人肝微粒体中的 NADH-细胞色素-c 还原酶和 S-美芬妥英 4-羟化酶活性。在细胞色素 b5 存在的情况下，所有五种纯化的细胞色素 P-450 制剂的 S-美芬妥英的 Km 值为 1.25 mM，Vmax 值为每分钟/nmol P-450 形成的 4-羟基产物 0.8-1.25 nmol。 P-45OMP 是一种相对选择性的 P-450 形式，可以很好地代谢取代的乙内酰脲。[2]
| Cas No. | 70989-04-7 | SDF | |
| 别名 | 甲秦皮素,(S)-5-Ethyl-3-methyl-5-phenylhydantoin | ||
| 化学名 | (5S)-5-ethyl-3-methyl-5-phenyl-2,4-imidazolidinedione | ||
| Canonical SMILES | O=C1[C@@](C2=CC=CC=C2)(CC)NC(N1C)=O | ||
| 分子式 | C12H14N2O2 | 分子量 | 218.3 |
| 溶解度 | 15mg/ml in ethanol;25mg/ml in DMSO;25mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.5809 mL | 22.9043 mL | 45.8085 mL |
| 5 mM | 0.9162 mL | 4.5809 mL | 9.1617 mL |
| 10 mM | 0.4581 mL | 2.2904 mL | 4.5809 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet